Arrowstreet Capital Limited Partnership Reduces Stake in Aurinia Pharmaceuticals Inc $AUPH

Arrowstreet Capital Limited Partnership reduced its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 3.0% during the 1st quarter, HoldingsChannel reports. The fund owned 3,284,368 shares of the biotechnology company’s stock after selling 102,826 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Aurinia Pharmaceuticals were worth $48,674,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AUPH. BOK Financial Private Wealth Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $32,000. Frazier Financial Advisors LLC increased its position in shares of Aurinia Pharmaceuticals by 411.9% during the 1st quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 2,793 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $48,000. Kemnay Advisory Services Inc. bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $82,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 1,318 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Aurinia Pharmaceuticals news, CEO Kevin Tang purchased 206,005 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was purchased at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the purchase, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. The trade was a 1.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders purchased 814,606 shares of company stock worth $12,455,129. 10.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

AUPH has been the subject of a number of analyst reports. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings cut shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $15.22 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. Aurinia Pharmaceuticals Inc has a 1-year low of $8.80 and a 1-year high of $19.25. The firm has a market capitalization of $1.96 billion, a P/E ratio of 7.01 and a beta of 1.41. The company’s 50-day moving average is $15.99 and its 200 day moving average is $15.36.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The business had revenue of $77.71 million during the quarter, compared to the consensus estimate of $76.98 million. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.81 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.